Mark Boldrin

XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study

Jarl Torgerson, Jonathan Hauptman, Mark Boldrin et al. · Diabetes Care · 2004 · 1.9K citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients

Lars Sjöström, Aila Rissanen, Teis Andersen et al. · The Lancet · 1998 · 1.2K citations

Agriculture, Nutrition, Nutritional Sciences +14

Effect of Orlistat on Weight and Body Composition in Obese Adolescents

Jean‐Pierre Chanoine, Sarah Hampl, Craig L. Jensen et al. · JAMA · 2005 · 624 citations

Agriculture, Pediatrics, Pharmacotherapy +17

Effects of Weight Loss With Orlistat on Glucose Tolerance and Progression to Type 2 Diabetes in Obese Adults

Steven B. Heymsfield, Karen R. Segal, Jonathan Hauptman et al. · Archives of Internal Medicine · 2000 · 359 citations

Medicine, Endocrinology, Pharmacotherapy +17

The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes

Julio Rosenstock, Bogdan Balas, B Charbonnel et al. · Diabetes Care · 2012 · 118 citations · Full text

Pharmacy, Endocrinology, Pharmacology +16